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Cobalamin (vitamin B12) deﬁciency is particularly common in the elderly (>65 years of age) but is often unrecognized because its
clinicalmanifestationsaresubtle;however,theyarealsopotentiallyserious,particularlyfromaneuropsychiatricandhematological
perspective. In the elderly, the main causes of cobalamin deﬁciency are pernicious anemia and food-cobalamin malabsorption.
Food-cobalamin malabsorption syndrome is a disorder characterized by the inability to release cobalamin from food or its binding
proteins. This syndrome is usually caused by atrophic gastritis, related or unrelated to Helicobacter pylori infection, and long-
term ingestion of antacids and biguanides. Management of cobalamin deﬁciency with cobalamin injections is currently well
documented but new routes of cobalamin administration (oral and nasal) are being studied, especially oral cobalamin therapy
for food-cobalamin malabsorption.
Copyright © 2008 Emmanuel Andr` es et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Cobalamin or vitamin B12 deﬁciency is common in elderly
patients [1] but is often unrecognized or not investigated
because the clinical manifestations of cobalamin deﬁciency
are subtle. However, the complications of cobalamin deﬁ-
ciency, particularly the neuropsychiatric and hematological
[1–4], are potentially serious and therefore require investiga-
tion in all patients who present with vitamin or nutritional
deﬁciency. Classic disorders such as pernicious anemia are
the cause of cobalamin deﬁciency in only a limited number
of patients, especially elderly patients [4]. A more common
problem is food-cobalamin malabsorption, a disorder char-
acterized by the inability to release cobalamin from food
or its binding proteins [4]. This review summarizes the
currentknowledgeoncobalamindeﬁciency,withaparticular
focus on food-cobalamin malabsorption and oral cobalamin
therapy.
2. Deﬁnition of CobalaminDeﬁciency
Literature of the last ten years has provided several deﬁ-
nitions of cobalamin deﬁciency [5–7]. The deﬁnitions of
cobalamindeﬁciencyusedinthisreviewareshowninTable 1
[7, 8]. To date, cobalamin deﬁciency is often deﬁned in
terms of the serum concentration of cobalamin and of
homocysteine and methyl malonic acid, two components of
the cobalamin metabolic pathway, (Figure 1) but in clinical
practice, no single test has emerged as the gold standard
for diagnosis of cobalamin deﬁciency especially in elderly
patients. Moreover, the major diagnostic challenge remains
patients who develop subtle cobalamin deﬁciency, often
without hematological abnormalities (usefulness of an early
treatment to prevent irreversible neurological damages) [4].
In the future, new serum cobalamin assay kits (e.g., the
holotranscobalamin assay kit) might perhaps replace older
assay kits and should become the standard for testing [6, 9].
3. Epidemiology of Cobalamin Deﬁciency
Epidemiological studies show that in the general population
of industrialized countries, cobalamin deﬁciency has a
prevalence of around 2 to 20%, depending on the deﬁnition
of cobalamin deﬁciency used [4, 9]. The Framingham study
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Figure 1: Cellular impact of cobalamin deﬁciency.
living in the community [10]. Other studies focusing on
elderly people, particularly those who are in institutions or
who are sick and malnourished, have suggested a higher
prevalence of at least 30% [11, 12]. Using the deﬁnition in
Table 1 (serum cobalamin levels <150pmol/L [<200 pg/mL]
on2separateoccasions),wefoundthatcobalamindeﬁciency
had a prevalence of 5% in a group of patients followed or
hospitalizedinatertiaryreferencehospital[8].Wealsodocu-
mentedthataround4%oftheanemiawererelatedtoacobal-
amin deﬁciency in a population of 300 consecutive anemia
hospitalized in our department (tertiary reference center)
[8]. In the NHANES III study, 34% of all anemia in elderly
patients is caused by folate, cobalamin, or iron deﬁciency,
alone or in combination (nutritient-deﬁciency anemia) [8].
4. Cobalamin Metabolism andFunction
Cobalamin metabolism is complex and is made up of many
processes, defects in any one of which can lead to cobalamin
deﬁciency [4, 13–15]. The diﬀerent stages of cobalamin
metabolism and corresponding causes of cobalamin deﬁ-
ciency are shown in Table 2. Once metabolized, cobalamin
is a cofactor and coenzyme for many biochemical reactions,
including DNA synthesis, methionine synthesis from homo-
cysteine,andconversionofpropionylintosuccinylcoenzyme
A from methyl malonate [4, 9]. In a clinical setting, cobal-
amin absorption is measured imperfectly by the Schilling
test [4, 8]. A typical Western diet contributes 3–30μgo f
cobalamin per day [13, 15] toward the recommended dietary
allowance of 2.4μg/day for adults and 2.6 to 2.8μg/day
Table 1: Deﬁnitions of cobalamin (vitamin B12) deﬁciency [5–7].
(i)Serumcobalaminlevels<150pmol/Landclinicalfeatures
and/or hematological anomalies related to cobalamin
deﬁciency
(ii) Serum cobalamin levels <150pmol/L (<200pg/mL) on 2
separate occasions
(iii)Serumcobalaminlevels<150pmol/Landtotalserumho-
mocysteine levels >13μmol/L or methylmalonic acid
levels >0.4μmol/L (in the absence of renal failure and
folate and vitamin B6 deﬁciencies)
(iv) Low serum holotranscobalamin levels <35pmol/L
during pregnancy [16]. The 5–10 year delay between the
onset of cobalamin deﬁciency and the development of
clinical illness is directly attributable to hepatic stores of
cobalamin (>1.5mg) and the enterohepatic cycle [4, 13].
Between 1–5% of free cobalamin (or crystalline cobalamin)
is absorbed along the entire intestine by passive diﬀusion.
This absorption explains the mechanism underlying oral
treatment of cobalamin deﬁciencies [17, 18].
5. ClassicalCausesof CobalaminDeﬁciency
In elderly patients, cobalamin deﬁciency is classically caused
by pernicious anemia and food-cobalamin malabsorption
[1,11,14].Theprincipalcharacteristicsofperniciousanemia
have been reported in detail in several reviews [19–21].
Diagnosis of pernicious anemia is based on the presenceCurrent Gerontology and Geriatrics Research 3
Table 2: Stages of cobalamin metabolism and corresponding causes of cobalamin deﬁciency [13, 15].
Stages and factors involved in cobalamin metabolism Causes of cobalamin deﬁciency
Ingestion of food
Strict vegetarianism (patients who are sick in institu-
tions or in psychiatric hospitals)
Digestion, which involves haptocorrin, gastric secretions (HCl and
pepsin), intrinsic factor, pancreatic and biliary secretions, and the
enterohepatic cycle
Gastrectomy, pernicious anemia, and food-cobalamin
malabsorption
Absorption, which brings into play intrinsic factor and cubilin Ileal resection, malabsorption, pernicious anemia, and
food-cobalamin malabsorption
Transportation by transcobalamins Congenital deﬁciency in transcobalamin II
Intracellular metabolism by various intracellular enzymes Congenital deﬁciency in various intracellular enzymes
HCl = hydrochloric acid.
Table 3: Food-cobalamin malabsorption syndrome [4, 14, 15].
Criteria for food-cobalamin malabsorption Associated conditions or agents
- Low-serum cobalamin (vitamin B12) levels
- Normal results of Schilling test using free cyanocobalamin labeled
with cobalt-58, or abnormal results of derived Schilling test‡
- No anti-intrinsic factor antibodies
- No dietary cobalamin deﬁciency
- Gastric disease: atrophic gastritis, type A atrophic gas-
tritis, gastric disease associated with Helicobacter pylo-
ri infection, partial gastrectomy, gastric by-pass, and
vagotomy
- Pancreatic insuﬃciency: alcohol
- Gastric or intestinal bacterial overgrowth: achlorhyd-
ria, tropical sprue, Ogylvie’s syndrome, and HIV
- Drugs: antacids (H2-receptor antagonists and proton-
pump inhibitors) or biguanides (metformin)
- Alcohol abuse
-S j¨ ogren’s syndrome, systemic sclerosis
- Haptocorrine deﬁciency
- Ageing or idiopathic
‡ Derived Schilling tests use food-bound cobalamin (e.g., egg yolk, chicken, and ﬁsh proteins).
of (1) intrinsic factor antibodies in serum (speciﬁcity:
>98%, sensibility: around 50%) and/or (2) autoimmune
atrophic gastritis (presence of Helicobacter pylori infection in
gastric biopsies is an exclusion factor) [15, 19]. Cobalamin
deﬁciency caused by dietary deﬁciency or malabsorption is
rare.Dietarycausesofdeﬁciencyarelimitedtoelderlypeople
who are already malnourished. This mainly concerns elderly
patients living in institutions or in psychiatric hospitals
[4, 13]. Since the 1980s, the malabsorption of cobalamin
has become rarer, owing mainly to the decreasing fre-
quency of gastrectomy and surgical resection of the terminal
small intestine [4, 14]. Several disorders commonly seen
in gastroenterology practice might, however, be associated
with cobalamin malabsorption. These include deﬁciency
in the exocrine function of the pancreas after chronic
pancreatitis (usually alcoholic), lymphomas or tuberculosis
(of the intestine), Crohn’s disease, Whipple’s disease, and
uncommonly celiac disease [11, 15].
6. Food-CobalaminMalabsorption
First, well-described by Carmel in 1995 [22], the food-
cobalamin malabsorption is a syndrome characterized by the
inability to release cobalamin from food or intestinal trans-
port proteins, particularly in the presence of hypochlorhy-
dria, in which the absorption of “unbound” cobalamin is
normal. As various studies have shown [14, 22, 23], this
syndrome is deﬁned by cobalamin deﬁciency in the presence
of suﬃcient food-cobalamin intake and normal Schilling test
results, which rules out malabsorption or pernicious anemia.
The principal characteristics of this syndrome are listed in
Table 3. In theory, indisputable evidence of food-cobalamin
malabsorption comes from using a modiﬁed Schilling test,
which uses radioactive cobalamin bound to animal proteins
(e.g., salmon, trout) and reveals malabsorption when the
results of a standard Schilling test are normal [4, 14, 23].
Food-cobalamin malabsorption has been found to be
the leading cause of cobalamin malabsorption, especially
in elderly patients [4, 11, 22]. In our experience (300
patients with a documented cobalamin deﬁciency), food-
cobalamin malabsorption accounts for about 60–70% of the
cases of cobalamin deﬁciency in elderly patients, whereas
pernicious anemia accounted for only 15–25% [14, 23].
Some authors have speculated about the reality and signif-
icance of cobalamin deﬁciency related to food-cobalamin
malabsorption [4], because many patients have only mild
clinical or hematological features. Several of our patients,
however, [14] had signiﬁcant features classically associ-
ated with pernicious anemia, including polyneuropathy,
confusion, dementia, medullar-combined sclerosis, anemia,
and a pancytopenia. Nevertheless, the partial nature of4 Current Gerontology and Geriatrics Research




manifestations Digestive manifestations Other manifestations
- Frequent: macrocytosis, hyper-
segmentation of the neutrophils,
aregenerative macrocytary ane-
mia, LDH and bilirubin eleva-
tion, medullary megaloblastosis
“(blue spinal cord)”
- Rare: isolated thrombocytopenia
and neutropenia, pancytopenia
- Very rare: hemolytic anemia,
thrombotic microangiopathy
(presence of schistocytes)
- Frequent: polyneurites (espe-
cially sensitive ones), ataxia,
Babinski’s phenomenon
- Classic: combined sclerosis
of the spinal cord
- Rare: cerebellar syndromes
aﬀecting the cranial nerves
including optic neuritis, op-
tic atrophy, urinary, and/or
fecal incontinence
- Under study: changes in the
higher functions, even de-





- Classic: Hunter’s glossitis, jaun-
dice, LDH and bilirubin eleva-
tion “(intramedullary destruc-
tion)”
- Debatable: abdominal pain,
dyspepsia, nausea, vomiting,
diarrhea, disturbances in intes-
tinal functioning
- Rare: resistant and recurring
mucocutaneous ulcers cobala-
min deﬁciency
- Under study: atrophy of the vag-
inal mucosa and chronic vaginal
and urinary infections (especial-
ly mycosis), hypofertility and re-
peated miscarriages (connection




this form of malabsorption might produce a more slowly
progressive depletion of cobalamin than does the more
complete malabsorption engendered by disruption of intrin-
sic factor-mediated absorption. The slower progression of
depletion probably explains why mild preclinical deﬁciency
isassociatedwithfood-cobalaminmalabsorptionmoreoften
than with pernicious anemia [4, 14].
Food-cobalamin malabsorption is caused primarily by
atrophic gastritis [14]. Achlorhydria hampers the extraction
of cobalamin from protein food sources. Over 40% of
patients older than 80 years of age have gastric atrophy that
might or might not be related to Helicobacter pylori infection
[11, 24]. Other factors that contribute to food-cobalamin
malabsorption in elderly people include chronic carriage of
H. pylori and intestinal microbial proliferation (in which
case cobalamin deﬁciency can be corrected by antibiotic
treatment)[24, 25]; long-term ingestion of antiacids, includ-
ing H2-receptor antagonists and proton-pump inhibitors
[26, 27], particularly among patients with Zollinger-Ellison
syndrome [28, 29], and biguanides (metformin) [30–32];
chronic alcoholism; surgery or gastric reconstruction (e.g.,
bypass surgery for obesity); partial pancreatic exocrine
failure [4, 14], and Sj¨ ogren’s syndrome or systemic sclerosis
[33]( Table 3). In a series of 92 elderly patients (mean
age: 76 years) with food-cobalamin malabsorption [14], we
have reported at least one of these associated conditions
or agents in 60% of the patients. These conditions mainly
includeatrophicgastritis(±H.pyloriinfection)in30%ofthe
patients and long-term metformin or antacid intake in 20%
of the elderly patients.
7. ClinicalManifestations of
Cobalamin Deﬁciency
The primary clinical manifestations of cobalamin deﬁciency
are described in Table 4. They are highly polymorphic and of
varying severity ranging from common sensory neuropathy
and isolated anomalies of macrocytosis and hypersegmenta-
tion of neutrophils, to severe disorders, including combined
sclerosis of the spinal cord, hemolytic anemia, and even
pancytopenia [2, 14, 34–36]. In the aforementioned series
of 92 patients with food-cobalamin malabsorption [14], we
have found at least one clinical feature or hematological
abnormalities in, respectively, 70% and 76% of the patients.
Cobalamin deﬁciency appears to be more common among
patients who have a variety of chronic neurologic conditions
such as dementia, Alzheimer’s disease, stroke, Parkinson’s
disease, and depression, although it is unclear if these
are causal relationships [4, 37]. In our own studies in
whichweadministeredcobalamintopatientswithdementia,
improvement was not observed [8, 14]. Other studies have
had similar results [1, 2, 9]. At this time, a causal role of
cobalamin in these conditions remains speculative.
8. ClassicalTreatment of Cobalamin Deﬁciency
The classic treatment for cobalamin deﬁciency, particu-
larly when the cause is not dietary deﬁciency, is par-
enteral administration—in most countries intramuscular
injection—of this vitamin (in the form of cyanocobalamin
and, more rarely, hydroxy or methyl cobalamin) [1, 17,
18, 34]. However, traditions concerning both dose and
schedule of administration vary considerably. In France, the
recommended practice is to build up the tissue stores of
the vitamin quickly and correct serum cobalamin hypovi-
taminosis, particularly in the case of pernicious anemia.
The treatment involves the administration of 1000μgo f
cyanocobalamin per day for 1 week, followed by 1000μgp e r
week for 1 month, followed by 1000μg per month, normally
for the rest of the patient’s life [11, 19]. In USA and UK,
dosages ranging from 100 to 1000μg per month [or every 2-
3 months when hydroxocobalamin is given] are used during
the rest of the patient’s life [4, 17]. Hydroxocobalamin may
have several advantages due to a better tissular retention and
storage. Additionally, recent works concern oral cobalamin
therapy through food fortiﬁcation [3, 11].Current Gerontology and Geriatrics Research 5
Table 5: Experience of oral cobalamin therapy for food-cobalamin malabsorption in the university hospital of Strasbourg, France.
Study characteristics (number of
patients) Therapeutic modalities Results
Open prospective study of well-docu-
mented cobalamin deﬁciency related
to food-cobalamin malabsorption (n
= 10)
Oral crystalline cyanocobalamin: 650μg
per day during at least 3 months
- Normalization of serum cobalamin
levels in 80% of the patients
- Signiﬁcant increase of hemoglobin
(Hb) levels (mean of 1.9g/dL) and
decrease of mean erythrocyte cell
volume (ECV) (mean of 7.8fL)
- Improvement of clinical abnormal-
ities in 20% of the patients
[41]
Open prospective study of low-cobal-
amin levels not related to pernicious
anemia (n = 20)
Oral crystalline cyanocobalamin: be-
tween 1000μg per day during at least 1
week
- Normalization of serum cobalamin
levels in 85% of the patients
-N oa d v e r s ee ﬀect
[42]
Open prospective study of well-docu-
mented cobalamin deﬁciency related
to food-cobalamin malabsorption (n
= 30)
Oral crystalline cyanocobalamin: be-
tween 1000 and 250μg per day during
1m o n t h
- Normalization of serum cobalamin
levels in 87% of the patients
-D o s ee ﬀect: eﬀectiveness dose of co-
balamin ≥500μg per day
-N oa d v e r s ee ﬀect
[40]
Open prospective study of low-cobal-
amin levels not related to pernicious
anemia (n = 30)
Oral crystalline cyanocobalamin: be-
tween 1000 and 125μg per day during
at least 1 week
- Signiﬁcant increase of Hb levels
(mean of 0.6g/dL) and decrease of
ECV (mean of 3fL); normalization
of Hb levels and ECV in 54% and
100% of the patients, respectively
- Normalization of serum cobalamin
levels in all patients with at least a
dose of vitamin ≥250μg per day
-D o s ee ﬀect: eﬀectiveness dose of co-
balamin ≥500μg per day
-N oa d v e r s ee ﬀect
[43]
Open prospective study of low cobal-
amin levels related to pernicious ane-
mia (n = 10)
Oral crystalline cyanocobalamin:1000
μg per day during at least 3 months
- Signiﬁcant increase of serum cobal-
amin levels in 90% of the patients
(mean of 117.4pg/mL)
- Signiﬁcant increase of Hb levels
(mean of 2.45g/dL) and decrease of
ECV (mean of 10.4fL)
- Improvement of clinical abnormali-
ties in 30% of the patients
[47]
9. Oral Cobalamin Therapy
Since cobalamin is absorbed by intrinsic factor-independent
passive diﬀusion (1% of oral cobalamin), daily high-dose
oral cyanocobalamin can induce and maintain remissions
in patients with megaloblastic anemia [15]. In cases of
cobalamin deﬁciency other than those caused by nutritional
deﬁciency, alternative routes of cobalamin administration
have been used: oral [17, 18, 38–44] and nasal [45, 46].
These other routes of administration have been proposed as
a way of avoiding the discomfort, inconvenience, and cost
of monthly injections. Our working group has developed
an eﬀective oral treatment of food-cobalamin malabsorption
[40–43] and for pernicious anemia [47] using crystalline
cobalamin (cyanocobalamin). Our principal studies of oral
cobalamin treatment (open, not randomized studies) are
described in Table 5 [40–43, 47]. These data conﬁrm the
previously reported eﬃcacy of oral crystalline cyanocobal-
amin, especially in food-cobalamin therapy [18, 36, 38].
All of our patients who were treated orally corrected their
cobalamin levels and at least two-thirds corrected their
hematological abnormalities [40–43, 47]. Moreover, one-
third of patients experienced a clinical improvement on
oral treatment. In most cases of food-cobalamin malab-
sorption, “low” cobalamin doses (i.e., 125–1000μgo fo r a l
crystalline cyanocobalamin per day) were used. These data
is in accordance with the results of the two prospective
randomized-controlled studies comparing oral cobalamin
with intramuscular cobalamin therapy [17, 39]. A systematic
review of randomized-controlled trials by the Vitamin B12
Cochrane Group supports the eﬃcacy of oral cobalamin
therapy, with a dose between 1000 and 2000μg given initially
daily and then weekly [48]. In this analysis, serum cobal-
amin levels increased signiﬁcantly in patients receiving oral
cobalamin and both groups of patients (receiving oral and
intramuscular treatment) had neurological improvement.
The Cochrane group concludes that daily oral therapy “may
be as eﬀective as intramuscular administration in obtaining
short term haematological and neurological responses in
cobalamin deﬁcient patients” [48]. Nevertheless to our6 Current Gerontology and Geriatrics Research
knowledge, the eﬀect of oral cobalamin treatment in patients
presenting severe neurological manifestations has not yet
been adequately documented. Thus until this has been done
parenteral cobalamin therapy is still to be recommended for
suchpatients.Inarandomized,parallel-group,double-blind,
dose-ﬁndingtrial,Eussenetal.showedthatthelowestdoseof
oral cyanocobalamin required to normalize mild cobalamin
deﬁciency is more than 200 times the recommended dietary
allowance of approximately 3μg daily (i.e., >500μgp e r
day) [49]. The procedure for oral cobalamin treatment
has, however, not been completely validated yet in real
life, particularly the long-term eﬃcacy [50]. To date, as
several authors suggest, oral cobalamin therapy remains
one of “medicine’s best kept secrets” [51]. Since loading
doses of cobalamin far exceed physiologic requirements,
clinical responses may result from pharmacologic eﬀects on
either cobalamin-related processes or on cellular functions
completely unrelated to the known biochemical actions of
cobalamin[52].Asaresult,bloodcobalamin,methylmalonic
acid and homocysteine values often fail to predict whether
or not a patient will respond to cobalamin therapy [53].
Nevertheless, the following can be proposed: ongoing sup-
plementation until associated disorders are corrected (e.g.,
by halting the ingestion of the oﬀending medication or
exogenosis, or by treating H. pylori infection or pancreatic
exocrine failure), lifelong administration or, when applica-
ble, sequential administration [54].
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